Associations of Antiphospholipid Antibodies With Splanchnic Vein Thrombosis
Authors:
- Xingshun QiXQXingshun Qi
- Valerio De StefanoVSValerio De Stefano
- Chunping SuCSChunping Su
- Ming BaiMBMing Bai
- Xiaozhong GuoXGXiaozhong Guo
- Daiming FanDFDaiming Fan
Open Access
- 1 January 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 94 (4) , e496
Abstract
Splanchnic vein thrombosis (SVT) refers to Budd–Chiari syndrome (BCS) and portal vein system thrombosis (PVST). Current practice guidelines have recommended the routine screening for antiphospholipid antibodies (APAs) in patients with SVT. A systematic review and meta-analysis of observational studies was performed to explore the association between APAs and SVT. The PubMed, EMBASE, and ScienceDirect databases were searched for all relevant papers, in which the prevalence of positive APAs or levels of APAs should be compared between BCS or noncirrhotic PVST patients versus healthy controls, or between cirrhotic patients with portal vein thrombosis (PVT) versus those without PVT. Fourteen studies were eligible. Only 1 study evaluated the role of APAs in BCS patients and found that positive immunoglobulin (Ig) G anticardiolipin antibody (aCL) was more frequently observed in BCS patients than in healthy controls; however, the associations of other APAs with BCS were not evaluated. Positive IgG aCL was more frequently observed in noncirrhotic patients with PVST than in healthy controls; however, other APAs, such as IgM aCL, lupus anticoagulants (LAs), anti-β 2 -glycoprotein-I antibody (aβ 2 GPI), and aβ 2 GPI-oxidized low-density lipoprotein antibody (ox-LDL) were not associated with noncirrhotic PVST. Positive unclassified aCL was more frequently observed in cirrhotic patients with PVT than in those without PVT; however, the association of IgG aCL and IgM aCL with the development of PVT in liver cirrhosis remained inconsistent among studies. The risk of BCS and noncirrhotic PVST might be increased by positive IgG aCL but not IgM aCL, LA, aβ 2 GPI, or aβ 2 GPI ox-LDL. However, the evidence regarding APAs in BCS originated from only 1 study. The association between APAs and PVT in liver cirrhosis was unclear.Keywords
This publication has 42 references indexed in Scilit:
- Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd‐Chiari syndrome: A systematic review and meta‐analysis of observational studiesJournal of Gastroenterology and Hepatology, 2012
- Antiphospholipid Antibodies and Antiphospholipid Syndrome: Role in Portal Vein Thrombosis in Patients With and Without Liver CirrhosisClinical and Applied Thrombosis/Hemostasis, 2010
- Clinical course of high‐risk patients diagnosed with antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- Vascular disorders of the liver # †Hepatology, 2009
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Antibody profiles for the diagnosis of antiphospholipid syndromeThrombosis and Haemostasis, 2005
- Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosisJournal of Hepatology, 2004
- Portal Vein Thrombosis after Variceal Endoscopic Sclerotherapy in Cirrhotic Patients: Role of Genetic ThrombophiliaEndoscopy, 2002
- Inherited trombophilic disorders in patients with portal vein thrombosisJournal of Hepatology, 2000
- Antiphospholipid antibodies and thrombosisThe Lancet, 1999